Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.


Autoria(s): Gonzalez de Castro, D.; Clarke, P.A.; Al-Lazikani, B.; Workman, P.
Data(s)

01/03/2013

Resumo

The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.

Identificador

http://pure.qub.ac.uk/portal/en/publications/personalized-cancer-medicine-molecular-diagnostics-predictive-biomarkers-and-drug-resistance(60a804dd-6f97-461f-9d78-100ad0f276b0).html

http://dx.doi.org/10.1038/clpt.2012.237

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Gonzalez de Castro , D , Clarke , P A , Al-Lazikani , B & Workman , P 2013 , ' Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. ' Clinical Pharmacology and Therapeutics , vol 93 , no. 3 , pp. 252-259 . DOI: 10.1038/clpt.2012.237

Palavras-Chave #Biomarkers, Tumor #Drug Resistance, Neoplasm #Humans #Medical Oncology #Neoplasms #Pathology, Molecular #Precision Medicine #Protein Kinase Inhibitors #Proto-Oncogene Proteins B-raf
Tipo

article